Forest posts 6% sales hike, beating estimates; Indian court won't block Januvia knockoffs;

@FiercePharma: Some good news for Forest Labs: Quarterly sales tick up 6% to almost $800M; Forest credits newer products. More | Follow @FiercePharma

 @CarlyHFierce: Former AstraZeneca exec Tony Zook officially in as new CEO of Vivus. News | Follow @CarlyHFierce

> Forest Laboratories ($FRX) posted a 6% uptick in quarterly sales to $796.9 million, beating analyst estimates; though the company credited its newer drugs, old products also turned in higher-than-expected sales. Report

> An Indian court declined to block Glenmark Pharmaceutical's knockoff versions of Merck's ($MRK) diabetes blockbusters Januvia and Janumet. Report

> U.K. cost-effectiveness watchdogs rejected Roche's ($RHHBY) MabThera as a treatment for a rare type of vasculitis. Report

> Pierre Fabre, founder of the French drugmaker that bears his name, has died at the age of 87. Release

> Belgium's UCB is taking as many as 15 drugmakers to court over their plans to sell copycat versions of its epilepsy treatment Vimpat. Report

> U.S. Vice President Joe Biden met with Indian officials yesterday amid calls from American business leaders to lobby for their better treatment in the country. Report

Medical Device News

@FierceMedDev: Oxford University blood test designed to screen for stress. Item | Follow @FierceMedDev

 @MarkHFierce: Google is the lead in SynapDx's $15.4M funding round - the trial for its autism Dx blood test is now under way. ICYMI yesterday | Follow @MarkHFierce

@DamianFierce: The FDA has changed its approach to medical device hackers, part of its new commitment to cybersecurity. Report | Follow @DamianFierce

> JenaValve lands $62.5M round for heart valve. More

> Baxter wins EU sign-off for $4B Gambro deal. News

> Medical devices help spur Israeli VC investment growth. Article

Biotech News

@FierceBiotech: ICYMI yesterday: First successful transplant of retinas made from embryonic stem cells. Article | Follow @FierceBiotech

 @JohnCFierce: Report: Big Pharma mounts secret attack against data transparency rule (some companies will never learn). ICYMI yesterday | Follow @JohnCFierce

@RyanMFierce: Biogen sees 'unlikely' link between Tecfidera and patient death. Story | Follow @RyanMFierce

> Cytokinetics patches up ALS drug trial after costly study snafu. More

> NYT: GlaxoSmithKline's China R&D audit found ethical breaches. Report

> Array BioPharma scores midstage success for asthma drug. Report

Biotech Research News

 @EmilyMFierce: Novartis MS drug prevents heart failure in animal study. Article | Follow @EmilyMFierce

> Retinas made from embryonic stem cells implanted into mice for the first time. News

> New 3-D model of diabetes target could shape drug design. Story

> Neural origins of menopausal hot flashes discovered. Item

> Revalesio drug alters Alzheimer's progression in animal model. Article

Pharma Manufacturing News

 @EricPFierce: Orphan drugs have become a key product for many companies. See why: Special report | Follow @EricPFierce

> Wockhardt FDA warning letter says QA staff tried to mislead inspectors. Report

> Drug shortages in Ireland getting worse. More

> New bill could free drug user fees from sequestration, improve oversight. Article

> Venus Remedies gets 9 Ukraine plants approved. Item

> AMRI gets issues under control at Burlington plant. Report

And Finally... Scientists search for biomarkers that show how fast people are aging. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.